{"filing":{"accession_number":"0001193125-26-269383","cik":"0001472012","ticker":"IMNM","company_name":"Immunome Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"imnm-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/imnm-20260609.htm"},"events":[{"id":10789,"run_id":9466,"accession_number":"0001193125-26-269383","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the final results of Immunome's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of three Class III directors (Boylan, Swain, Wagenheim), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.","company_name":"Immunome Inc.","ticker":"IMNM","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7189,"accession_number":"0001193125-26-269383","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final results of Immunome's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of three Class III directors (Boylan, Swain, Wagenheim), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:47.360848+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7189,"accession_number":"0001193125-26-269383","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final results of Immunome's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of three Class III directors (Boylan, Swain, Wagenheim), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:47.360848+00:00","company_name":"Immunome Inc.","ticker":"IMNM","filing_date":"2026-06-12"}]}